MARKET

NVCT

NVCT

Nuvectis Pharma, Inc.
NASDAQ
23.99
+1.50
+6.67%
After Hours: 23.99 0 0.00% 19:30 09/11 EDT
OPEN
22.96
PREV CLOSE
22.49
HIGH
24.24
LOW
22.28
VOLUME
221.08K
TURNOVER
--
52 WEEK HIGH
29.28
52 WEEK LOW
5.55
MARKET CAP
781.63M
P/E (TTM)
-18.3396
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NVCT last week (0831-0904)?
Weekly Report · 4d ago
This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Benzinga · 09/04 15:57
Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)
TipRanks · 09/03 12:30
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Benzinga · 09/02 15:32
This PG&E Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Benzinga · 09/01 16:05
This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Benzinga · 08/31 13:18
This Deere Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Benzinga · 08/31 13:16
Weekly Report: what happened at NVCT last week (0824-0828)?
Weekly Report · 08/31 10:11
More
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.

Webull offers Nuvectis Pharma Inc stock information, including NASDAQ: NVCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCT stock methods without spending real money on the virtual paper trading platform.